-
UN approves resolution on dealing with rising sea levels
-
Klopp denied on Germany debut as Portugal win in Nations League
-
Yalcouye makes dream debut as Ivory Coast beat Ghana in AFCON qualifier
-
Rich nations should foot climate bill, says Nepal minister
-
Chicago's White Sox and Cubs book MLB playoff berths
-
Wellalage and Mendis star as Sri Lanka level England series in thriller
-
Last-gasp Gakpo strike snatches Dutch draw to sour Klopp debut
-
Felix gives Portugal win over Wales as Ronaldo misfires
-
Global stocks mostly fall as oil prices and bond yields rise
-
Wellalage and Mendis star as Sri Lanka level England ODI series
-
Israel's Netanyahu denounces enemies, allies in fiery UN speech
-
Guyana urges Venezuela at UN to respect ICJ's ruling on Essequibo region
-
Hollywood stars among arrests in NY anti-Netanyahu protest
-
Argentina coach says Messi deserves to go out on own terms
-
Losing start in AFCON qualifying for 78-year-old coach Le Roy
-
Xi sets red lines for Trump despite lavish White House welcome
-
Italy bans burqas in schools, caps numbers of foreign students per class
-
Cowboys, Ravens happy with footing for first Rio NFL clash
-
Israel policies threaten 'life and existence' of Palestinians, Abbas says
-
Starbucks to close 250 more cafes in North America
-
Paolini steers Italy past China in BJK
-
French actress Marina Vlady dies at 88
-
Zidane admits emotion on eve of first game as France coach
-
CNN, MS NOW, Politico allowed back in White House after judge's order
-
Breetzke and Maharaj sink Australia in first one-day international
-
Morocco's ruling coalition dominates low-turnout parliament election
-
Zelensky broke confidentiality with North Korea POWs disclosure: South's president
-
Napoli hoping to build new stadium, says owner
-
Former Liverpool star Carroll reveals he was sexually assaulted
-
What's behind the Pakistani strikes on Afghanistan?
-
Dominican Republic calls for Haiti force to be strengthened
-
Hundreds protest for return of Nobel peace laureate Machado to Venezuela
-
Dolly Parton's nephew ordered to stay away from estate staff, properties
-
Aubameyang to miss two months for Deportivo after knee surgery
-
Early exit for Philippine darling Eala at Singapore Open
-
Newsom says Trump presidency 'as we know it' ends in November
-
Hurricane Polo triggers huge waves in coastal Mexican city
-
Stocks fall as oil prices rise and bonds back under pressure
-
What happens if the US bans diesel exports
-
Russell leads Mercedes 1-2 in Azerbaijan GP practice
-
Macklemore hits back with 'Free Palestine Tour' after Sheeran split
-
Ukrainian kills priest, wounds four at Polish abbey
-
Met Opera to give New Yorkers free tickets in affordability push
-
Sri Lanka captain Mendis hits century in 321-6 against England
-
Top ECB official to resign to take up IMF role
-
Oscar-winner Cotillard fears being moved by AI actor
-
Xi and Trump call for peace in lavish White House state visit
-
Agassi demands proper break for exhausted tennis stars
-
Five up-and-coming players looking to make mark in Nations League
-
Seixas 'crushes' teammates in training to draw Pogacar comparisons
Moderna sues Pfizer, BioNTech for Covid-19 vaccine patent infringement
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"This groundbreaking technology was critical to the development of Moderna's own mRNA Covid-19 vaccine, Spikevax. Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna added.
US-based Pfizer said it has not received the lawsuit and declined to speak further, while Germany's BioNTech did not immediately reply to a request for comment.
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are both safe and effective.
The lawsuits -- to be filed in filed Friday both in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on coronaviruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
G.Schulte--BTB